The Trendlines Group
The Trendlines Building
Misgav Business Park
17 T'chelet Street
M.P. Misgav 2017400 • Israel

For Immediate Release

Trendlines' total portfolio value increases to US$86.9 million

- **Total income of US$1.1 million for 1Q2016, lower than 1Q2015 primarily due to change in fair value of investments in Portfolio Companies**
- **Income from contracted R&D services increased to US$0.3 million from US$0.1 million supported by new collaboration agreements in relation to R&D services provided by Trendlines Labs**
- **Net loss of US$0.8 million for 1Q2016**
- **Multiple achievements in establishing strategic partnerships with renowned multinational companies year to date, to enhance deal flow and future growth**

Singapore, 10 May 2016 – The Trendlines Group Ltd. (the "**Company**", and together with its subsidiaries and associated companies, the "**Group**"), an Israeli company focused on developing technology-based companies in the medical and agricultural fields, announced its financial results for the three months ended 31 March 2016 ("1Q2016") today.

	1Q2016	1Q2015	Change
	US$'000	US$'000	%
Gain(loss) from change in fair value of investments in Portfolio Companies	(992)	1,202	N.M.
Income from services to portfolio companies	1,281	1,231	4.0
Income from contracted R&D services	330	102	223.2
Total income	1,140	3,160	(63.9)
Total expenses	2,633	2,218	18.7
Net income (loss) and total comprehensive income (loss)	(770)	580	N.M.

*N.M.: Not meaningful

Total income for the Group was US$1.1 million in 1Q2016, compared to US$3.2 million in 1Q2015. The reduction in total income is primarily attributable to a net loss in the fair value of investments in portfolio companies of US$1 million, compared to a net gain in 1Q2015 amounting to US$1.2 million. This net loss in the fair value of portfolio companies in 1Q2016 takes into account an increase of US$3.9 million in the fair value of the Most Valuable Portfolio Company[1], as well as an aggregate fair value gain of US$0.6 million for some other portfolio companies as a result of the completion of fund raising exercises at favourable valuations and general commercial and technological progress during the quarter. However, this gain was offset by an aggregate fair value loss of US$4.8 million, as a result of the completion of fund raising exercises for some other portfolio companies at less favourable terms to the Company, as well as general commercial or technological difficulties in some companies and the write off of two portfolio companies during the quarter in the amount of US$1.0 million.

Income from services to portfolio companies remained relatively unchanged in 1Q2016 as compared to 1Q2015. Income from contracted R&D services increased to US$0.3 million from US$0.1 million due to new collaboration agreement in relation to R&D services provided by Trendlines Labs to a third party.

[1] As defined in the Company's offer document dated 16 November 2015

Our loss before taxes was US$1.5 million for the quarter compared to a gain of approximately US$0.9 million in first quarter of 2015.

Income tax for the quarter was a tax benefit of approximately US$0.7, due to the effect of reduction in the deferred taxes which was caused mainly by the reduction in tax rate from 26.5% to 25%. This resulted in a net loss for the quarter of US$0.8 million, compared to a profit of US$0.5 million in 1Q2015.

The Group maintained a strong financial position. As at 31 March 2016, the Group had cash and cash equivalents of US$8.2 million, compared to US$7.0 million as at 31 December 2015. Current assets as at 31 March 2016 were $21.5 million, as compared to US$24.0 million at the end of 2015. The reduction in current assets reflects investments in our portfolio companies and current operations during the first quarter which reduced short term investments to US$12.0 million, from US$16.4 million on 31 December 2015.

The fair value of all the portfolio companies ("**portfolio value**"), including the fair value of a company carried at equity value, as at 31 March 2016 was approximately US$86.9 million, compared to US$85.8 million as at 31 December 2015. The increase was primarily attributable to an increase of US$3.9 million in the fair value of the Most Valuable Portfolio Company.

Commenting on the 1Q2016 financial results, Mr. D. Todd Dollinger, Co-Chairman and CEO of the Group, said, "The nature of our business has two distinct characteristics in our financials as compared to that of any traditional business. Firstly, the fair value of our portfolio companies changes according to the progress in their fund raising and technological and commercial development, and the varying rates of progress at different companies could lead to variations in fair value on a portfolio level from quarter to quarter. Secondly, as significant monetary gain is generated chiefly by exits from our portfolio companies, the financial performance and earnings can be volatile.

"Trendlines' value to portfolio companies lies in providing support ranging from technological development and business development to marketing and fund raising. Our goal is to assist portfolio companies to achieve a relatively smooth growth path to commercialization, and to eventually exit from these investments with optimal returns. We are working hard to achieve this goal, and we will update the market as exit projects materialize."

Mr. Steve Rhodes, Co-Chairman and CEO of the Group, added, “Despite the quarterly numbers, we made a promising start for 2016. We entered into a definitive collaboration agreement with B. Braun on establishing mutual deal flow and the development of new technologies; Bayer AG committed US$10 million in the Bayer Trendlines Agtech Innovation Fund which will focus on making early-stage agritech investments and will be managed by Trendlines. Separately, Trendlines Labs entered into a collaboration agreement with a major MNC headquartered in Japan to develop innovative medical device products for manufacturing and marketing by the Japanese MNC. Trendlines Labs also received an additional order from a large U.S. medical device company, following its successful collaboration with the company earlier.

“These partnerships are an endorsement of Trendlines’ business model and our R&D capabilities. Collaboration with these industry leaders in their respective fields will raise Trendlines’ visibility in the medical and agricultural technologies space, provide us with a larger platform to improve human condition, stimulate our growth, and enhance the potential for us to generate long-term value to our shareholders.”

- The End -

Issued for and on behalf of The Trendlines Group Ltd.
By Financial PR Pte Ltd.

For more information, please contact:

Romil SINGH / Reyna MEI
romil@financialpr.com.sg / reyna@financialpr.com.sg
Tel: (65) 6438 2990, Fax: (65) 6438 0064

The Trendlines Group Ltd. (the "Company") was listed on Catalist of the Singapore Exchange Securities Trading Limited (the "SGX-ST") on 26 November 2015. The initial public offering of the Company was sponsored by PrimePartners Corporate Finance Pte. Ltd. (the “Sponsor"). This press release has been prepared by the Company and its contents have been reviewed by the Sponsor for compliance with

the SGX-ST Listing Manual Section B: Rules of Catalist. The Sponsor has not verified the contents of this press release. This press release has not been examined or approved by the SGX-ST. The Sponsor and the SGX-ST assume no responsibility for the contents of this press release, including the accuracy, completeness or correctness of any of the information, statements or opinions made or reports contained in this press release. The contact person for the Sponsor is Ms Gillian Goh, Director, Head of Continuing Sponsorship, at 16 Collyer Quay, #10-00 Income at Raffles, Singapore 049318, telephone (65) 6229 8088.